If patients did not meet the BP goal with the maximum tolerated dose of the initial medication, an open-label step 2 agent (atenolol, 25-100 mg/day; reserpine, 0.05-0.2 mg/day; or clonidine ...
The VALUE trial compared the effect of an ARB (valsartan) with a CCB (amlodipine), both in the whole cohort as well as in the diabetic subgroup. No significant difference in the composite cardiac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback